NX-1607 demonstrated on-target peripheral immune activation characteristic of an active immune-oncology agent with a novel immune checkpoint mechanism distinct from PD-1/PD-L1 therapies NX-1607 ...

CDC and Florida Health Department researchers found seven risk factors that can lead to clinical Candida auris cases. The study, published Oct. 2 in Clinical Infectious Diseases, analyzed patients in ...

We recently published 10 Stocks With Double-Digit Upsides. Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is one of the top performers on Thursday. Sarepta Therapeutics extended its winning streak to a 5th ...

Publication title: “Oral Blarcamesine Phase IIb/III Trial Confirms Identified Precision Medicine Patient Population – Significant Broad Clinical and Quality of Life Improvements for Early Alzheimer’s ...

NEW YORK, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative ...

OIC India Enhances On-Site Capabilities with Structured Clinical and Digital Dentistry Training SEOUL, South Korea, Sept. 22, 2025 /PRNewswire/ -- Osstem Implant (CEO: Haesung Kim), the world's No. 3 ...

RICHMOND, Va. (WRIC) — A $7.3 million grant will fund a groundbreaking breast cancer clinical trial at Virginia Commonwealth University (VCU) Massey Comprehensive Cancer Center, health officials said.

The inherent variability and potential inaccuracies of AI-generated output can leave even experienced clinicians uncertain about AI recommendations. This dilemma is not novel; it mirrors the broader ...

SAN FRANCISCO, July 09, 2025 (GLOBE NEWSWIRE) -- A securities class action lawsuit styled Ho v. Rocket Pharmaceuticals, Inc., et al., No. 3:25-cv-10049 (D. N.J.) has been filed and seeks to represent ...

If you enjoyed this article, I’d like to ask for your support. Scientific American has served as an advocate for science and industry for 180 years, and right now may be the most critical moment in ...

Claudin18.2 (CLDN18.2) expression and efficacy in pancreatic ductal adenocarcinoma (PDAC): Results from a phase I dose expansion cohort evaluating IBI343. 10-year follow up of a phase 2 clinical trial ...